Added Eira Bio, an antibody therapeutics company, to the Fund III portfolio.
Added recently
Biotechnology company developing antibody-based biologics against challenging multi-pass membrane proteins, including GPCRs, ion channels, and solute transporters
Biotechnology company developing antibody-based biologics against challenging multi-pass membrane proteins, including GPCRs, ion channels, and solute transporters. Its yeast-based synthetic biology and directed-evolution platforms discover, evolve, and optimize precision antibodies for diseases with unmet medical needs.